Pre-Issuance, Industry-Standard Monitoring and Copying of a Product Does Not Support a Finding of Willful Infringement of Method of Use Patent

Mar 31, 2020

Reading Time : 2 min

Plaintiffs Bioverativ Inc., Bioverativ Therpaeutics Inc. and Bioverativ U.S. LLC (collectively “Bioverativ”) sued defendants CSL Behring LLC, CSL Behring GmbH and CSL Behring Lengau AG (collectively “CSL”) for infringement of three patents directed to methods of treating hemophilia by administering a chimeric factor IX (FIX) polypeptide according to claimed dosing regimens. Bioverativ further alleged that CSL willfully infringed the claims based on its sale of Idelvion®, a chimeric FIX polypeptide that comprises FIX and albumin as its binding partner.

In support of its willfulness allegations, Bioverativ alleged that CSL developed its product using confidential information it obtained from Bioverativ’s predecessor during discussions to co-develop and manufacture a half-life extended FIX product—discussions that occurred before the priority date and nearly a decade before the patents issued. Bioverativ further alleged that CSL targeted the same dosing regimen that was disclosed in confidence. Bioverativ also pointed to CLS’s monitoring of Phase III clinical data to match the dosing interval, arguing that CSL was attempting to “match” Bioverativ’s dosing interval.

On summary judgment, the court disagreed that Bioverativ’s allegations could support a finding of willfulness or enhanced damages. Specifically, the court found that none of CSL’s pre-issuance activities constituted willful infringement. First, the court explained that monitoring clinical trials does not show copying. At most, it shows an interest in how clinical trials are progressing, which amounts to competitive intelligence gathering. And because the parties agreed that competitive intelligence is “standard in the pharmaceutical industry,” such pre-patent surveillance activities, without more, do not amount to “elaborate copying” or “consciously wrongful,” “malicious” behavior. Likewise, the use of confidential information obtained nearly seven years before the patents issued in 2017 relating to a pharmaceutical product could not support a finding of willful infringement of method of treatment claims.

The court also addressed the alleged post-issuance activities and found they too did not rise to the level of wanton, malicious and bad-faith behavior necessary for willful infringement. Notably, the product accused of practicing the claimed methods entered the market more than a year before the patents issued. In other words, at the time it was launched, it did not infringe any of the asserted patents. And, as a result, there could be no willful infringement until the litigation was filed. The court noted that this timeline necessarily complicated matters for both parties. For the plaintiff, it was difficult to identify any difference in the defendants’ pre-issuance and post-issuance activities. Here, knowledge of the patents at the time of their issuance was undisputed. But no other post-issuance evidence existed to support a finding of willful infringement, and there was no evidence that the claimed methods of treatment were copied. For these reasons, the court granted summary judgment of no willful infringement.

Practice Tips:

  • Evidence that a party is acting consistently with industry standards may help refute allegations of willful infringement, but it may not be sufficient to negate evidence of direct copying. Therefore, companies engaged in competitive monitoring should be cognizant of the manner in which information is collected and disseminated.
  • In a similar vein, patentees asserting claims of willful infringement should identify evidence that indicates an accused infringer’s conduct goes beyond standard monitoring. This may be particularly true in cases where a patent to methods of treatment issues after a product used in the method enters the market.

Bioverativ Inc. v. CSL Behring LLC, No. 17-914-RGA (D. Del. Mar. 23, 2020)

Share This Insight

Previous Entries

IP Newsflash

August 5, 2025

The Federal Circuit recently vacated a decision by the Patent Trial and Appeal Board after concluding that the board’s analysis of licensing evidence offered as a secondary consideration of nonobviousness constituted legal error and was not supported by substantial evidence. According to the court, the board applied a more exacting and improperly heightened nexus standard than is required by law for license evidence.

...

Read More

IP Newsflash

August 5, 2025

In a recent decision designated as Informative, the USPTO Director determined that the Patent Trial and Appeal Board abused its discretion by instituting two inter partes review proceedings challenging the same patent, based on petitions advancing different constructions of the same claim term. The Director expressed concerns that permitting multiple petitions based on alternative claim constructions effectively circumvents word count limitations, strains board resources, and undermines procedural efficiency.

...

Read More

IP Newsflash

July 25, 2025

Earlier this year, the Federal Circuit’s decision in Qualcomm Inc. v. Apple Inc. (Qualcomm II) raised questions about the extent to which petitioners can rely on applicant admitted prior art (“AAPA”) in inter partes review proceedings.  The Federal Circuit’s recent decision in Shockwave Medical, Inc. v. Cardiovascular Sys., Inc. largely cabins the Qualcomm II decision to its particular facts and makes clear that AAPA can be used as evidence of background knowledge as part of an obviousness argument.

...

Read More

IP Newsflash

July 11, 2025

The Federal Circuit recently reversed a PTAB determination on remand that a patent was obvious over applicant admitted prior art (“AAPA”) in combination with prior art patents, holding that expressly designating AAPA as a “basis” for a ground is improper under 35 U.S.C. § 311(b). In doing so, the Court rejected the PTAB’s “blanket rule” that “AAPA used in combination with prior art patents or printed publications under § 311(b) is ipso facto not the basis or part of the basis of a ground.” Ultimately, while the case clarifies that expressly listing AAPA in an IPR ground is improper, the precise line between proper and improper uses of AAPA in other instances remains unclear.

...

Read More

IP Newsflash

July 1, 2025

In an appeal from an inter partes review, the Federal Circuit recently clarified that the enablement inquiry applied to prior art references in the context of an anticipation defense differs from the enablement inquiry applied when evaluating the claims of a patent.

...

Read More

IP Newsflash

June 26, 2025

The Northern District of Ohio denied a motion to compel the plaintiff to produce test results referenced in its initial disclosures and complaint. The court found that because the “test results are not facts but rather are opinions,” the information was protected as work product. Furthermore, because that testing would not be used as evidence in the litigation, the defendant was not prejudiced.

...

Read More

IP Newsflash

June 6, 2025

In a precedential opinion, the Federal Circuit definitively held that the Patent Trial and Appeal Board has jurisdiction over IPRs that concern expired patents.

...

Read More

IP Newsflash

June 6, 2025

In a patent infringement litigation in the U.S. District Court for the Eastern District of Texas, Judge Rodney Gilstrap denied a joint motion to stay the litigation pending resolution of inter partes review when it was uncertain that all defendants would be bound by the statutory estoppel provision of 35 U.S.C. § 315(e).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.